Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma

Am J Hematol. 2009 Feb;84(2):71-3. doi: 10.1002/ajh.21328.


Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • B-Cell Activating Factor / blood*
  • B-Cell Activating Factor / genetics
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Lymphoma, Follicular / blood
  • Lymphoma, Follicular / drug therapy*
  • Male
  • Middle Aged
  • Neoplasm Proteins / blood*
  • Neoplasm Proteins / genetics
  • Polymorphism, Single Nucleotide*
  • Retrospective Studies
  • Rituximab


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • B-Cell Activating Factor
  • Neoplasm Proteins
  • TNFSF13B protein, human
  • Rituximab